Barclays Adjusts Elevance Health (ELV) PT to $393 While Maintaining Overweight Rating

4 days ago 4

Maham Fatima

Sat, January 31, 2026 astatine 6:48 AM CST 1 min read

Elevance Health Inc. (NYSE:ELV) is 1 of the most undervalued ample headdress stocks to put successful now.. On January 30, Barclays lowered the firm’s terms people connected Elevance Health to $393 from $404 and kept an Overweight standing connected the shares.

On January 29, Guggenheim expert Jason Cassorla besides lowered the firm’s terms people connected Elevance Health to $396 from $414 and maintained a Buy standing connected recalibrated 2026 estimates pursuing the company’s Q4 2025 report.

However, connected the aforesaid day, Deutsche Bank raised the firm’s terms people connected Elevance Health Inc. (NYSE:ELV) to $332 from $320 portion maintaining a Hold standing connected the shares. This determination was made arsenic the steadfast suggested that the company’s 2026 outlook whitethorn correspond a floor.

15 States with the Best Healthcare successful the US

Furthermore, UBS besides lowered the firm’s terms people connected Elevance Health to $400 from $425 with a Buy rating.

Elevance Health Inc. (NYSE:ELV), unneurotic with its subsidiaries, operates arsenic a wellness benefits institution successful the US. It has 4 segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.

While we admit the imaginable of ELV arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.